Orchestra BioMed Holdings, Inc. (OBIO)
Nasdaq · Healthcare · Biotechnology
$6.03+1.34%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $362M
- 52-week range
- $2.66 – $6.50
- 52-week change
- +120.88%
- EPS (trailing)
- −$0.86
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $33.5M (+1169.22%)
- Net income
- −$52.7M
- Operating margin
- −154.7%
- Diluted EPS
- −$1.11
- Free cash flow
- −$49.5M
From the company’s annual report on SEC EDGAR.
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc.
Headquarters: New Hope, United States · 86 employees · orchestrabiomed.com